Literature DB >> 19842711

Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor.

Valentín Mendoza1, M Magdalena Vilchis-Landeros, Guillermo Mendoza-Hernández, Tao Huang, Maria M Villarreal, Andrew P Hinck, Fernando López-Casillas, Jose-Luis Montiel.   

Abstract

Betaglycan is a coreceptor for members of the transforming growth factor beta (TGF-beta) superfamily. Mutagenesis has identified two ligand binding regions, one at the membrane-distal and the other at the membrane-proximal half of the betaglycan ectodomain. Here we show that partial plasmin digestion of soluble betaglycan produces two proteolysis-resistant fragments of 45 and 55 kDa, consistent with the predicted secondary structure, which indicates an intervening nonstructured linker region separating the highly structured N- and C-terminal domains. Amino terminal sequencing indicates that the 45 and 55 kDa fragments correspond, respectively, to the membrane-distal and -proximal regions. Plasmin treatment of membrane betaglycan results in the production of equivalent proteolysis-resistant fragments. The 45 and 55 kDa fragments, as well as their recombinant soluble counterparts, Sol Delta10 and Sol Delta11, bind TGF-beta, but nonetheless, compared to intact soluble betaglycan, have a severely diminished ability to block TGF-beta activity. Surface plasmon resonance (SPR) analysis indicates that soluble betaglycan has K(d)'s in the low nanomolar range for the three TGF-beta isoforms, while those for Sol Delta10 and Sol Delta11 are 1-2 orders of magnitude higher. SPR analysis further shows that the K(d)'s of Sol Delta11 are not changed in the presence of Sol Delta10, indicating that the high affinity of soluble betaglycan is a consequence of tethering the domains together. Overall, these results suggest that betaglycan ectodomain exhibits a bilobular structure in which each lobule folds independently and binds TGF-beta through distinct nonoverlapping interfaces and that linker modification may be an approach to improve soluble betaglycan's TGF-beta neutralizing activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19842711      PMCID: PMC2796082          DOI: 10.1021/bi901528w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  28 in total

Review 1.  TGFbeta signaling in growth control, cancer, and heritable disorders.

Authors:  J Massagué; S W Blain; R S Lo
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

3.  Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions.

Authors:  Ezra Wiater; Craig A Harrison; Kathy A Lewis; Peter C Gray; Wylie W Vale
Journal:  J Biol Chem       Date:  2006-04-18       Impact factor: 5.157

4.  Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor.

Authors:  Gregory De Crescenzo; Cynthia S Hinck; Zhanyong Shu; Jorge Zúñiga; Junhua Yang; Yuping Tang; Jason Baardsnes; Valentín Mendoza; LuZhe Sun; Fernando López-Casillas; Maureen O'Connor-McCourt; Andrew P Hinck
Journal:  J Mol Biol       Date:  2005-11-02       Impact factor: 5.469

5.  Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.

Authors:  K A Lewis; P C Gray; A L Blount; L A MacConell; E Wiater; L M Bilezikjian; W Vale
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

6.  Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent.

Authors:  M M Vilchis-Landeros; J L Montiel; V Mendoza; G Mendoza-Hernández; F López-Casillas
Journal:  Biochem J       Date:  2001-04-01       Impact factor: 3.857

7.  Soluble betaglycan reduces renal damage progression in db/db mice.

Authors:  Patricia Juárez; M Magdalena Vilchis-Landeros; José Ponce-Coria; Valentín Mendoza; Rogelio Hernández-Pando; Norma A Bobadilla; Fernando López-Casillas
Journal:  Am J Physiol Renal Physiol       Date:  2006-09-05

8.  The type III TGF-beta receptor suppresses breast cancer progression.

Authors:  Mei Dong; Tam How; Kellye C Kirkbride; Kelly J Gordon; Jason D Lee; Nadine Hempel; Patrick Kelly; Benjamin J Moeller; Jeffrey R Marks; Gerard C Blobe
Journal:  J Clin Invest       Date:  2006-12-07       Impact factor: 14.808

9.  Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.

Authors:  Abhik Bandyopadhyay; Long Wang; Fernando López-Casillas; Valentín Mendoza; I-Tien Yeh; LuZhe Sun
Journal:  Prostate       Date:  2005-04-01       Impact factor: 4.104

10.  Expression, purification and characterization of BG(E)RII: a novel pan-TGFbeta inhibitor.

Authors:  Erik V Verona; Yuping Tang; Thomas K Millstead; Andrew P Hinck; Joseph K Agyin; Lu-Zhe Sun
Journal:  Protein Eng Des Sel       Date:  2008-05-21       Impact factor: 1.650

View more
  22 in total

Review 1.  Structural Biology and Evolution of the TGF-β Family.

Authors:  Andrew P Hinck; Thomas D Mueller; Timothy A Springer
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-12-01       Impact factor: 10.005

2.  TGF-β signalling is mediated by two autonomously functioning TβRI:TβRII pairs.

Authors:  Tao Huang; Laurent David; Valentín Mendoza; Yong Yang; Maria Villarreal; Keya De; LuZhe Sun; Xiaohong Fang; Fernando López-Casillas; Jeffrey L Wrana; Andrew P Hinck
Journal:  EMBO J       Date:  2011-03-18       Impact factor: 11.598

3.  Proteolytic control of TGF-β co-receptor activity by BMP-1/tolloid-like proteases revealed by quantitative iTRAQ proteomics.

Authors:  Frédéric Delolme; Cyril Anastasi; Lindsay B Alcaraz; Valentin Mendoza; Sandrine Vadon-Le Goff; Maya Talantikite; Robin Capomaccio; Jimmy Mevaere; Laëtitia Fortin; Dominique Mazzocut; Odile Damour; Isabelle Zanella-Cléon; David J S Hulmes; Christopher M Overall; Ulrich Valcourt; Fernando Lopez-Casillas; Catherine Moali
Journal:  Cell Mol Life Sci       Date:  2014-09-27       Impact factor: 9.261

Review 4.  Signaling Receptors for TGF-β Family Members.

Authors:  Carl-Henrik Heldin; Aristidis Moustakas
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

Review 5.  Structural biology of betaglycan and endoglin, membrane-bound co-receptors of the TGF-beta family.

Authors:  Sun Kyung Kim; Morkos A Henen; Andrew P Hinck
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-10

Review 6.  ALK1 signaling in development and disease: new paradigms.

Authors:  Beth L Roman; Andrew P Hinck
Journal:  Cell Mol Life Sci       Date:  2017-09-04       Impact factor: 9.261

7.  Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat.

Authors:  Angela Y Chen; Frank A DeLano; Shakti R Valdez; Jessica N Ha; Hainsworth Y Shin; Geert W Schmid-Schönbein
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-22       Impact factor: 4.249

8.  Fibroblast growth factor-2 promotes in vitro mitral valve interstitial cell repair through transforming growth factor-β/Smad signaling.

Authors:  Li Han; Avrum I Gotlieb
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

9.  Structural Adaptation in Its Orphan Domain Engenders Betaglycan with an Alternate Mode of Growth Factor Binding Relative to Endoglin.

Authors:  Sun Kyung Kim; Matthew J Whitley; Troy C Krzysiak; Cynthia S Hinck; Alexander B Taylor; Christian Zwieb; Chang-Hyeock Byeon; Xiaohong Zhou; Valentín Mendoza; Fernando López-Casillas; William Furey; Andrew P Hinck
Journal:  Structure       Date:  2019-07-18       Impact factor: 5.006

10.  The type III TGF-β receptor betaglycan transmembrane-cytoplasmic domain fragment is stable after ectodomain cleavage and is a substrate of the intramembrane protease γ-secretase.

Authors:  Cheyne R Blair; Jacqueline B Stone; Rebecca G Wells
Journal:  Biochim Biophys Acta       Date:  2010-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.